Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
McKinsey
Merck
Johnson and Johnson

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 5,840,690

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,840,690
Title: Regulation of cell proliferation and differentation using peptides
Abstract:Disclosed are methods of inhibiting proliferation and enhancing differentiation of a mammalian cell, inducing proliferation of a mammalian cell, enhancing wound healing, and stimulating hair growth using a peptide which has 10% or greater homology to a region of human parathyroid hormone or human hypercalcemic factor.
Inventor(s): Holick; Michael F. (Sudbury, MA)
Assignee:
Application Number:08/471,576
Patent Claims:1. A method of inhibiting proliferation or enhancing differentiation of a mammalian skin cell, said method comprising contacting a mammalian skin cell in need of inhibited proliferation or enhanced differentiation with a proliferation-inhibiting or differentiation-enhancing amount of a peptide selected from the group consisting of human parathyroid hormone (hPTH), human hypercalcemic factor (hCFF), a hPTH agonist and a hCFF factor agonist,

wherein said agonist peptides are at least 8 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 4 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of inhibiting proliferation or enhancing the differentiation in vitro of cultured human keratinocytes.

2. A method of inhibiting proliferation or enhancing differentiation of a mammalian skin cell, said method comprising contacting a mammalian skin cell in need of inhibited proliferation or enhanced differentiation with a proliferation-inhibiting or differentiation-enhancing amount of a peptide selected from the group consisting of hPTH, hCFF, a hPTH agonist and a hCFF agonist,

wherein said agonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 4 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of inhabiting proliferation or enhancing the differentiation in vitro of cultured human keratinocytes.

3. A method of treating a hyperproliferative skin disorder in a mammal, said method comprising contacting a mammalian skin cell in need thereof with an effective amount of a peptide selected from the group consisting of hPTH, hCFF, a hPTH agonist and a hCFF agonist,

wherein said agonist peptides are at least 8 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 4 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of inhibiting proliferation or enhancing the differentiation in vitro of cultured human keratinocytes.

4. A method of treating a hyperproliferative skin disorder in a mammal, said method comprising contacting a mammalian skin cell in need thereof with an effective amount of a peptide selected from the group consisting of hPTH, hCFF, a hPTH agonist and a hCFF agonist,

wherein said agonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 4 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of inhibiting proliferation or enhancing the differentiation in vitro of cultured human keratinocytes.

5. The method of any one of claims 1-4, wherein said contacting comprises administering topically to the skin of said mammal.

6. The method of claim 2 or 4, wherein said peptide is a hPTH or hCFF agonist having at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF.

7. The method of any one of claims 1 and 3, wherein said peptide is a hPTH or hCFF agonist having at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF.

8. The method of any one of claims 1-4, wherein the carboxy terminal amino acid of said peptide is an amide.

9. The method of any one of claims 1-4, wherein said peptide is hPTH (1-34).

10. The method of any one of claims 1-4, wherein said peptide is hCFF (1-34) amide.

11. The method of claim 3 or 4, wherein said hyperproliferative skin disorder is psoriasis.

12. A method of inducing proliferation of a mammalian skin cell, said method comprising contacting a mammalian skin cell in need of enhanced proliferation with a proliferation-inducing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 8 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

13. A method of inducing proliferation of a mammalian skin cell, said method comprising contacting a mammalian skin cell in need of enhanced proliferation with a proliferation-inducing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

14. The method of claim 12 or 13, wherein said contacting comprises administering topically to the skin of a mammal.

15. The method of claim 13, wherein said peptide is a hPTH or hCFF antagonist having at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF.

16. The method of claim 12 or 13, wherein said peptide is a hPTH antagonist having at least 8 amino acids in common with the 34 amino acid N-terminal region of hPTH.

17. The method of claim 12 or 13, wherein the carboxy terminal amino acid of said peptide is an amide.

18. The method of claim 12, wherein said peptide is bovine (Tyr.sup.34) PTH (7-34) amide.

19. The method of claim 12, wherein said peptide is bovine (Nle.sup.8,18,Tyr.sup.34) PTH (7-34) amide.

20. The method of claim 12, wherein said peptide is hCFF (7-34).

21. The method of claim 12 or 13, wherein said mammalian skin cell is a hair cell.

22. A method of enhancing healing of a skin wound in a mammal in need thereof, said method comprising contacting said manual with a wound-healing enhancing amount of a peptide which is a hCFF antagonist,

wherein said antagonist peptide is at least 8 amino acids long, said peptide contains a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptide is capable of enhancing wound healing in an in vivo skin punch assay.

23. A method of enhancing healing of a skin wound in a mammal in need thereof, said method comprising contacting said mammal with a wound-healing enhancing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of enhancing wound healing in an in vivo skin punch assay.

24. The method of claim 22 or 23, wherein said peptide is a hPTH antagonist having at least 8 amino acids in common with the 34 amino acid N-terminal region of hPTH.

25. The method of claim 22 or 23, wherein the carboxy terminal amino acid of said peptide is an amide.

26. The method of claim 22, wherein said peptide is bovine (Tyr.sup.34) PTH (7-34) amide.

27. The method of claim 22, wherein said peptide is bovine (Nle.sup.8,18,Tyr.sup.34) PTH (7-34) amide.

28. The method of claim 23, wherein said peptide is hCFF (1-34) amide.

29. A method of enhancing or maintaining hair growth in a mammal, said method comprising administering to a mammal in need thereof a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 8 amino acids long, said peptides contain a fragment of 8 amino acids which has 8 amino acids in common with the 34 amino acid N-terminal region of hPTH or at least 6 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of enhancing hair growth in an in vitro hair growth assay.

30. A method of enhancing or maintaining hair growth in a mammal, said method comprising administering to a mammal in need thereof a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 4 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of enhancing hair growth in an in vitro hair growth assay.

31. The method of claim 30, wherein said peptide is a hPTH or hCFF antagonist having at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF.

32. The method of claim 29 or 30, wherein said peptide is a hPTH antagonist having 8 amino acids in common with the 34 amino acid N-terminal region of hPTH.

33. The method of claim 29 or 30, wherein the carboxy terminal amino acid of said peptide is an amide.

34. The method of claim 29, wherein said peptide is bovine (Tyr.sup.34) PTH (7-34) amide.

35. The method of claim 25, wherein said peptide is bovine (Nle.sup.8,18,Tyr.sup.34) PTH (7-34) amide.

36. The method of claim 29, wherein said peptide is hCFF (7-34).

37. The method of claim 29 or 30, wherein said method is a method of enhancing or maintaining hair growth following chemotherapeutic treatment of said mammal.

38. A method of stimulating epidermal regrowth in a mammal in need thereof, said method comprising administering to said mammal a skin growth enhancing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 8 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

39. A method of stimulating epidermal regrowth in a mammal in need thereof, said method comprising administering to said mammal a skin growth enhancing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 8 amino acids which has at least 6 amino acids in common with the 34 amino acid N-terminal region of hPTH or 8 amino acids in common with the 34 amino acid N-terminal region of hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

40. The method of claim 38 or 39, wherein said peptide is a hPTH antagonist having at least 8 amino acids in common with the 34 amino acid N-terminal region of hPTH.

41. The method of claim 39, wherein said peptide is a hPTH or hCFF antagonist having at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF.

42. The method of claim 32 or 39, wherein the carboxy terminal amino acid of said peptide is an amide.

43. The method of claim 32, wherein said peptide is bovine (Tyr.sup.34) PTH (7-34) amide.

44. The method of claim 38, wherein said peptide is bovine (Nle.sup.8,18,Tyr.sup.34) PTH (7-34) amide.

45. The method of claim 38, wherein said peptide is hCFF (7-34).

46. The method of any one of claims 1, 2, 3 and 4, wherein said peptide comprises a fragment of the 34 amino acid N-terminal region of hPTH or hCFF of at least 8 amino acids in length.

47. The method of any one of claims 12, 13, 22, 23, 29, 30, 38, and 39, wherein said peptide is administered topically to the skin of said mammal.

48. A method of inducing proliferation of a mammalian skin cell, said method comprising contacting a mammalian skin cell in need of enhanced proliferation with a proliferation-inducing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 34 amino acids which has at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

49. A method of enhancing healing of a skin wound in a mammal in need thereof, said method comprising contacting said mammal with a wound-healing enhancing amount of a peptide which is a hCFF antagonist,

wherein said antagonist peptide is at least 34 amino acids long, said peptide contains a fragment of 34 amino acids which has at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptide is capable of enhancing wound healing in an in vivo skin punch assay.

50. A method of enhancing or maintaining hair growth in a mammal, said method comprising administering to a mammal in need thereof a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 3 4 amino acids long, said peptides contain a fragment of 34 amino acids which has at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of enhancing hair growth in an in vitro hair growth assay.

51. A method of stimulating epidermal regrowth in a mammal in need thereof, said method comprising administering to said mammal a skin growth enhancing amount of a peptide selected from the group consisting of a hPTH antagonist and a hCFF antagonist,

wherein said antagonist peptides are at least 34 amino acids long, said peptides contain a fragment of 34 amino acids which has at least 17 amino acids in common with the 34 amino acid N-terminal region of hPTH or hCFF, and said peptides are capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH (1-34), 1,25(OH).sub.2 D.sub.3 or CFF (1-34).

52. The method of claim 22, wherein said peptide is CFF (7-34).

Details for Patent 5,840,690

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial 2015-11-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial 2015-11-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial 2015-11-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial 2015-11-24 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Colorcon
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.